Is HUMA or IBO more undervalued in 2026?

CirclFi compares Humacyte, Inc. (HUMA) and Impact BioMedical, Inc. (IBO) using 13 institutional-grade valuation models. HUMA has a Quality of Company score of 3.5/10 while IBO scores 4.4/10.

Which is a better buy — HUMA or IBO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HUMA and IBO valuations compare?

HUMA at $1.28 and IBO at $0.51 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HUMA vs IBO Valuation Comparison 2026 — Intrinsic Value Analysis

HUMA

Biotechnology

Humacyte, Inc.

Quality

3.5

out of 10

Value Trap

LOW

Price

$1.28

Last close

Models

5/13

Active

IBO

Biotechnology

Impact BioMedical, Inc.

Quality

4.4

out of 10

Value Trap

SAFE

Price

$0.51

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	HUMA Fair Value	HUMA Upside	IBO Fair Value	IBO Upside
Bayesian DCF	Intrinsic	$0.35	-73.0%	$0.12	-76.3%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.36	-72.2%	$0.02	-95.1%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HUMA vs IBO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HUMA vs IBO — Which Stock Is More Undervalued?

IBO scores higher with a 4.4/10 quality rating vs HUMA's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Humacyte, Inc. (HUMA) and Impact BioMedical, Inc. (IBO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HUMA currently trades at $1.28 with a QOC of 3.5/10, while IBO trades at $0.51 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).